On Sept. 9, 2025, Eli Lilly announced the launch of Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform that provides biotech companies access to drug discovery models trained on years of Lilly’s research data.

Lilly estimates that this first release of AI models includes proprietary data obtained at a cost of over $1 billion, representing one of the industry’s most valuable datasets used to train an AI system available to biotechnology companies. 

Lilly TuneLab is powered by Lilly’s full drug disposition, safety, and preclinical datasets representing experimental data obtained with hundreds of thousands of unique molecules. In return for access, selected biotech partners contribute training data, which fuels continuous improvement for the benefit of others in the ecosystem and ultimately patients.

The platform is hosted by a third-party and employs federated learning, a privacy-preserving approach that enables biotechs to tap into Lilly’s AI models without directly exposing their proprietary data or Lilly’s. Lilly TuneLab was developed through partnerships with leading global technology providers and AI/ML experts. Lilly intends to extend the platform’s features and capabilities beyond this first release, including adding in vivo small molecule predictive models, available exclusively on Lilly TuneLab.

Lilly TuneLab is the newest addition to Lilly Catalyze360’s set of offerings for Lilly’s biotech partners, which includes strategic capital through Lilly Ventures, state-of-the-art laboratory facilities at Lilly Gateway Labs, and drug development expertise via Lilly ExploR&D.